Optimal Allocation of Resources across Four Interventions for Type 2 Diabetes
暂无分享,去创建一个
Anke Richter | Stephen W. Sorensen | Ping Zhang | Stephanie R. Earnshaw | David F. Williamson | D. Williamson | E. Gregg | Ping Zhang | T. Hoerger | A. Richter | Edward Gregg | Katherine A. Hicks | K. V. Venkat Narayan | Thomas J. Hoerger | K. M. Venkat Narayan | K. Hicks | Michael Engelgau | Ted Thompson | S. Earnshaw | M. Engelgau | Ted Thompson | K. Venkat Narayan | K. Venkat Narayan
[1] A. Bates,et al. Prioritization of health care services. A progress report by the Oregon Health Services Commission. , 1991, Archives of internal medicine.
[2] J. Baron,et al. Cost-effectiveness analysis in a setting of budget constraints--is it equitable? , 1996, The New England journal of medicine.
[3] Chen Mm,et al. Maximizing health system output with political and administrative constraints using mathematical programming. , 1976 .
[4] Roy M. Anderson,et al. Spatial heterogeneity and the design of immunization programs , 1984 .
[5] B. Davis,et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. , 1998, Circulation.
[6] J. Rawles. Castigating QALYs. , 1989, Journal of medical ethics.
[7] E. H. Kaplan. Economic Evaluation and HIV Prevention Community Planning , 1998 .
[8] R. Holman,et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .
[9] E. H. Kaplan. Economic Evaluation and HIV Prevention Community Planning A Policy Analyst's Perspective , 1998 .
[10] M L Brandeau,et al. Optimal Investment in a Portfolio of HIV Prevention Programs , 2001, Medical decision making : an international journal of the Society for Medical Decision Making.
[11] Eric R. Zieyel. Operations research : applications and algorithms , 1988 .
[12] A. Zbrozek,et al. Model of Complications of NIDDM: I. Model construction and assumptions , 1997, Diabetes Care.
[13] K. Flegal,et al. Prevalence of Diabetes, Impaired Fasting Glucose, and Impaired Glucose Tolerance in U.S. Adults: The Third National Health and Nutrition Examination Survey, 1988–1994 , 1998, Diabetes Care.
[14] R. Kaplan. Value Judgment in the Oregon Medicaid Experiment , 1994, Medical care.
[15] D N Mendelson,et al. Health care expenditures for people with diabetes mellitus, 1992. , 1994, The Journal of clinical endocrinology and metabolism.
[16] 康生 大久保,et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus : a randomized prospective 6-year study , 1995 .
[17] E. Araki,et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. , 1995, Diabetes research and clinical practice.
[18] Robert Fabian,et al. Valuing health for policy : an economic approach , 1995 .
[19] J. Kahn,et al. The cost-effectiveness of HIV prevention targeting: how much more bang for the buck? , 1996, American journal of public health.
[20] A. Zbrozek,et al. Model of Complications of NIDDM: II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia , 1997, Diabetes Care.
[21] Ronald L. Rardin,et al. Optimization in operations research , 1997 .
[22] A Gafni,et al. Guidelines for the adoption of new technologies: a prescription for uncontrolled growth in expenditures and how to avoid the problem. , 1993, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[23] R. Carr-Hill,et al. Assumptions of the QALY procedure. , 1989, Social science & medicine.
[24] T O Tengs,et al. Oregon's Medicaid Ranking and Cost- Effectiveness , 1996, Medical decision making : an international journal of the Society for Medical Decision Making.
[25] Edward H. Kaplan,et al. Allocating HIV prevention resources , 1998 .
[26] D. Hadorn. The Oregon Priority-setting Exercise , 1996, Medical decision making : an international journal of the Society for Medical Decision Making.
[27] P. Macfarlane,et al. West of Scotland Coronary Prevention Study: Identification of high-risk groups and comparison with other cardiovascular intervention trials , 1996 .
[28] R. Nelson,et al. Justice and the moral acceptability of rationing medical care: the Oregon experiment. , 1992, The Journal of medicine and philosophy.
[29] G S Zaric,et al. Resource allocation for epidemic control over short time horizons. , 2001, Mathematical biosciences.
[30] A A Stinnett,et al. Mathematical programming for the efficient allocation of health care resources. , 1996, Journal of health economics.
[31] A. Hillman,et al. Competing Practice Guidelines: Using Cost-Effectiveness Analysis To Make Optimal Decisions , 1998, Annals of Internal Medicine.
[32] S M Teutsch,et al. The role of resource allocation models in selecting clinical preventive services. , 1999, The American journal of managed care.
[33] Anke Richter,et al. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. , 2002, JAMA.
[34] Philip D. Harvey,et al. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 , 1998, BMJ.
[35] S. Cobbe. Baseline risk factors and their association with outcome in the West of Scotland Coronary Prevention Study. The West of Scotland Coronary Prevention Study Group. , 1997, The American journal of cardiology.
[36] A H van Zon,et al. Patient flows and optimal health‐care resource allocation at the macro‐level: a dynamic linear programming approach , 1999, Health care management science.
[37] J. Blumstein. The Oregon experiment: the role of cost-benefit analysis in the allocation of Medicaid funds. , 1997, Social science & medicine.
[38] E. Nord. Health Status Index Models for Use in Resource Allocation Decisions: A Critical Review in the Light of Observed Preferences for Social Choice , 1996, International Journal of Technology Assessment in Health Care.
[39] D K Owens,et al. An Analysis of Optimal Resource Allocation for Prevention of Infection with Human Immunodeficiency Virus (HIV) in Injection Drug Users and Non-Users , 1999, Medical decision making : an international journal of the Society for Medical Decision Making.
[40] P. Macfarlane,et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .
[41] P. Singer. Resource allocation: beyond evidence-based medicine and cost-effectiveness analysis. , 1997, ACP journal club.
[42] V. Hasselblad,et al. Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation. Agency for Health Care Policy and Research. , 1997, JAMA.
[43] Herbert W. Hethcote,et al. Epidemiological models for heterogeneous populations: proportionate mixing, parameter estimation, and immunization programs , 1987 .
[44] N. Ray,et al. Economic Consequences of Diabetes Mellitus in the U.S. in 1997 , 1998, Diabetes Care.
[45] Milton C. Weinstein,et al. Valuing health care: From cost–effectiveness ratios to resource allocation: where to draw the line? , 1995 .